Pacific Edge Limited has released a shareholder letter providing an update on recent developments and strategic directions. The letter emphasizes the company's focus on capital preservation as it aims to regain Medicare coverage. Details regarding a planned Share Purchase Plan (SPP) are included, which will be offered to eligible retail shareholders at the same price as a recent placement, expected to open in mid-July. The SPP and shareholder approval of the placement are essential for maintaining momentum and responding strategically to challenges and opportunities. The letter also highlights the inclusion of Cxbladder in the American Urological Association's guideline as a significant milestone. Shareholders are encouraged to review the SPP documentation and the Notice of Annual Shareholders' Meeting to be held in Auckland on 6 August 2025. The full letter can be accessed through the link below.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。